Apollomics (APLM) and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.
The deal entitles Apollomics to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.
Apollomics will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.
Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.
Shares of Apollomics jumped 12% in recent trading.
Price: 8.29, Change: +0.89, Percent Change: +12.03
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。